Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program
16 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
08 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders - - CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation,...
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 janv. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology
16 nov. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference
11 nov. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
10 nov. 2020 16h05 HE
|
Clearside Biomedical, Inc.
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2 Trials Using SCS Microinjector® Ongoing...
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020
30 oct. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina
23 sept. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery
11 sept. 2020 08h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe
26 août 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...